Wikidata

(Q64644818)

English

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

clinical trial

In more languages

Statements

short name
RESONATE™ (English)
0 references
title
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (English)
0 references
medical condition
lymphoma
0 references
leukemia
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
France
0 references
Republic of Ireland
0 references
Italy
0 references
Poland
0 references
Spain
0 references
United Kingdom
0 references
start time
June 2012
0 references
end time
November 2013
0 references
number of participants
391
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64644818&oldid=1857845012"